UroGen Pharma Announces Positive Interim Results from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
163
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

Interim Results Showed Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade UTUC

CRs to Date Remain Durable at Three, Six and Nine-Month Follow-Up

RA’ANANA, Israel and NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN ), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced new findings from an interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel™), an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC). Results were presented by Seth Paul Lerner, M.D., FACS, Principal Investigator of the OLYMPUS trial and Professor of Urology at Baylor College of Medicine in Houston in an oral presentation during the plenary session at the 113 th American Urological Association’s (AUA) Annual Meeting in San Francisco.

The interim analysis from this international, multi-center trial showed a complete response (CR) rate of 59 percent in 34 patients who were evaluated for primary disease evaluation (PDE, or the primary endpoint). PDE is conducted four to six weeks after completion of UGN-101 treatment, which was administered once weekly for six weeks. Results showed that 20 of the interim analysis intent to treat population of 34 patients (59 percent) achieved a CR, defined as a negative ureteroscopic evaluation and a negative wash cytology. In addition, five of 34 patients (15 percent) achieved a partial response. Approximately 39 percent of tumors treated were categorized as unresectable by surgery at baseline. The CRs to date have been durable. Of the 20 patients who achieved a CR, 13 patients have reached three-month follow-up and all remain in CR. Four of these 13 patients have reached six-month follow-up and one of the 13 patients has reached nine-month follow-up. All remain in CR. 

UGN-101 appeared to be well-tolerated with most treatment-emergent adverse events characterized as mild or moderate and transient.  These included urinary tract infection, flank pain, ureteral narrowing and hydronephrosis and time-limited creatinine elevation.

“These interim data from the OLYMPUS trial are promising and demonstrate the potential of UGN-101 to become the first drug ever approved for low-grade UTUC. We are pleased to see that the results to date from this trial improve upon the 44 percent complete response rate on an intent to treat basis observed in our similarly designed Compassionate Use program of UGN-101,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “Currently, the thousands of patients living with UTUC do not have many therapeutic options to manage their disease. With UGN-101, we hope to change the treatment paradigm for low-grade UTUC by potentially enabling the treatment of these tumors by non-surgical means, sparing patients from the risks and complications associated with repetitive surgical procedures and potential kidney removal.”

“We are excited about the interim analysis from our pivotal Phase 3 trial of UGN-101 presented today. This is an important step toward our anticipated Q1 2019 submission of a New Drug Application to the U.S. Food and Drug Administration,” said Ron Bentsur, Chief Executive Officer of UroGen. “This interim analysis also demonstrates the potential of our proprietary RTGel™ sustained release platform, which we believe has the potential to transform existing treatment paradigms across a number of urologic conditions. We look forward to continuing to advance our pipeline towards this end.”

The OLYMPUS trial continues to enroll patients, and top-line results are expected in the second half of 2018.

Details of AUA Oral Presentation Abstract #: LBA-25 Session: Plenary, Next Frontier Title: Non-Surgical Management of Low-Grade Upper Tract Urothelial Cancer: An Interim Analysis of the International Multicenter OLYMPUS Trial Presenter: Seth Paul Lerner, M.D., FACS, Professor of Urology, Baylor College of Medicine Time: Monday, May 21, 2018, 10:40-10:50 AM PDT Location: MCC NORTH, Hall E, The Moscone Center

About the Phase 3 OLYMPUS Trial OLYMPUS (Optimized DeLivery of Mitomycin for Primary UTUC Study) is a pivotal, open-label, single-arm Phase 3 clinical trial of UGN-101 (MitoGel™) to evaluate the safety, tolerability and tumor ablative effect of UGN-101 in patients with low-grade UTUC. The trial, designed to be a single pivotal study for the approval of UGN-101 in low-grade UTUC, is anticipated to enroll approximately 74 patients at clinical sites across the United States and Israel. Study participants are treated with six weekly instillations of UGN-101 administered via a standard catheter. Four to six weeks following the last instillation, patients undergo primary disease evaluation (PDE) to determine response, the primary endpoint of the study.  PDE involves a ureteroscopy and wash cytology, a standard microscopic test of cells obtained from the urine to detect cancer. Patients who achieve a complete response at the PDE timepoint will be followed for up to 12 months to determine the durability of disease control with UGN-101.

About Upper Tract Urothelial Cancer (UTUC) Upper tract urothelial cancer (UTUC) is a malignancy involving the lining of the ureters, renal pelvis and kidneys. In the United States, there are approximately 7,500 new cases of UTUC each year. Of these, about 2,500 cases are low-grade UTUC. Approximately 14,500 people are currently living with low-grade UTUC.

The current standard of care for UTUC is complete or partial surgical removal of the involved kidney or ureter. For patients with a bilateral disease, an anatomic or functionally solitary kidney, medical comorbidities or low-grade disease who present with a limited number of tumors, a kidney-conserving alternative is considered, if possible. However, due to the specific anatomy and physiology of the upper urinary tract and renal pelvis, organ-sparing endoscopic resection and instillation of neoadjuvant or adjuvant chemotherapy is often challenging, leading to high rates of recurrence. Additionally, continuous urine flow, the inability of the upper urinary tract to retain a liquid volume under normal circumstances, and the effects of peristalsis, or muscle contraction, result in short exposure time of active agents in the target area. This leads to poor efficacy and limited use of standard therapeutic agents in the treatment of UTUC.

About UGN-101 (MitoGel™) UGN-101 is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of low-grade UTUC. Utilizing the RTGel™ technology platform, UroGen’s proprietary sustained release, hydrogel-based formulation, UGN-101 is designed to enable longer exposure of mitomycin C to the urinary tract tissue, thereby potentially enabling the treatment of tumors by non-surgical means. UGN-101 is delivered to patients using standard intravesical catheters.

The U.S. Food and Drug Administration has granted both Orphan Drug and Fast Track designations to UGN-101 for the treatment of low-grade UTUC.

About UroGen Pharma Ltd. UroGen Pharma Ltd. (Nasdaq: URGN ) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 (MitoGel™, also known as mitomycin urothelial gel) and UGN-102 (VesiGel™, also known as mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.

Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the timing and results of clinical development and commercial prospects of the product candidates in UroGen’s pipeline, including UGN-101 (MitoGel™) and UGN-102 (VesiGel™), the scope and development of UroGen’s product candidate pipeline, enrollment in the OLYMPUS trial, timing and expectations of results from the OLYMPUS trial, UroGen’s expectations regarding its ability to fund its operations, and the ability of UroGen to become a leader in the field of uro-oncology, particularly in the treatment of low-grade UTUC, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential complications thereof, including with respect to enrollment; the timing of and the ability to obtain and maintain regulatory approval; interim data from the OLYMPUS trial not being indicative of future results; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; and the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of our annual report for the year ended December 31, 2017 filed with the SEC on March 15, 2018 and other filings that UroGen makes with the SEC from time to time (which are available at  http://www.sec.gov ), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

UROGEN CONTACT:

Kate Bechtold Director, Corporate Communications & Investor Relations KateB@urogen.com 914-552-0456 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 87

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
NCPDP Elevates J.W. Hill to President & COO Role

Updated Category News Views 46

Plotting the Course for NCPDP's Future Today's shakeup at the NCPDP has got the sector's ears perked. For those who don't speak in acronym soup all day—NCPDP stands for National Council for Prescription Drug Programs. They're the brains behind many crucial healthcare standards, improving information flow around meds, supplies, and services. Now, they're taking bold...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 104

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 103

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 173

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 102

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 65

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Organizations: RockDove Solutions on Crisis Communication

Updated Category News Views 111

Understanding the Importance of Crisis Communication Plans In today's fast-paced world, effective crisis communication is more critical than ever for businesses. Surprisingly, fewer than half of U.S. companies have formal crisis communication strategies in place. This statistic highlights a significant gap in business continuity planning, where communication often...

Continue Reading
Hafnia Limited Reports Strong Earnings for Q3 2024 Period

Updated Category News Views 83

Hafnia Limited Reports Strong Earnings for Q3 2024 Period Hafnia Limited (“Hafnia” or “the Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a premier product tanker company with an extensive and modern fleet exceeding 130 vessels, has recently reported promising financial results for the three and nine months ended September 30, 2024. Key...

Continue Reading
Recent Shareholding Changes at Irish Continental Group PLC

Updated Category News Views 138

Understanding Director and PDMR Shareholding Notifications In the world of corporate governance, transparency plays a crucial role in maintaining trust, particularly when it comes to senior management and directors. Recent notifications reveal key transactions involving persons discharging managerial responsibilities (PDMRs) at Irish Continental Group plc. Overview of...

Continue Reading
Experience the Summer Vibes at Coastal Mississippi Events

Updated Category News Views 220

Summer Events in Coastal Mississippi Come Play Coastal all summer long with seafood feasts, fireworks, car shows, and more! Ready to turn up the fun this summer? Coastal Mississippi is bringing a thrilling lineup of unforgettable events, all set against the backdrop of 62 miles of beautiful shoreline. From fresh seafood to electrifying fireworks, sensational car shows,...

Continue Reading
GUNNAR Optiks and 2K Games Unveil Exciting New Glasses

Updated Category News Views 197

GUNNAR Optiks Partners with 2K Games for New Glasses GUNNAR Optiks, a frontrunner in combating digital eye strain and a pioneer in blue light blocking eyewear, has teamed up with 2K Games to introduce an exciting new collection inspired by the much-anticipated Borderlands 4. This striking collection unveils its first eyewear style, aptly named the Ripper, marking the...

Continue Reading